Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Get a like-new iPad Air, wireless Beats Flex, and accessories for under $100
Myanmar media guide
OpenAI researchers warned of powerful AI discovery before CEO fired
The Best Floodlight Cameras for 2023
How to watch Pixar's visual treat 'Elemental' at home for free (almost)
Inworld AI, the Leading Character Engine, Raises New Funding From Lightspeed, Stanford, Microsoft’s M12 Fund, First Spark (Eric Schmidt), and More, Bringing Valuation to Over $500 Million
Scientists claim human ancestors lived alongside dinosaurs
ChatGPT creator Sam Altman ‘nervous’ about AI election manipulation